BioSpace News Archive

epocrates, the #1 medical reference app that enables more than one million prescribers to make confident point-of-care decisions, announced it has entered into a strategic partnership with ConnectiveRx, a leading provider of technology-enabled patient support and access solutions for specialty and branded medications.

Aptinyx Inc. (Nasdaq: APTX), a clinical-stage biopharmaceutical company developing transformative therapies for the treatment of nervous system disorders, today reported financial results for the first quarter of 2021 and highlighted recent progress across the company’s pipeline of novel, clinical-stage, NMDA receptor modulators.

Flexion Therapeutics, Inc. (Nasdaq:FLXN) announced today that Michael Clayman, M.D., President and Chief Executive Officer, will participate in an analyst-led fireside chat at the RBC Capital Markets 2021 Virtual Global Healthcare Conference.

Cohen Children’s Medical Center began vaccinating adolescents, aged 12 to 15, the youngest population yet in the race toward herd immunity against coronavirus disease 2019.

MediciNova, Inc., (Nasdaq: MNOV, JASDAQ:4875), a biopharmaceutical company developing small-molecule therapeutics, today reported financial results for the first quarter ended March 31, 2021 and provided a business update

Second Sight Medical Products, Inc., a leading developer of implantable visual prosthetics that are intended to create an artificial form of useful vision for blind individuals, announced that the Company received notice from the National Institutes of Health of the release of year three funding for its Early Feasibility Clinical Trial of a Visual Cortical Prosthesis, grant UH3NS103442.

Genetron Holdings Limited, a leading precision oncology platform company in China that specializes in offering molecular profiling tests, early cancer screening products and companion diagnostics development, announced a strategic partnership with Siemens Healthineers at the China Medical Equipment Fair.

Synlogic, Inc., a clinical stage company bringing the transformative potential of synthetic biology to medicine, reported financial results for the first quarter ended March 31, 2021, and provided an update on its clinical and preclinical programs.

Demonstrated lead program YMTX-7739 inhibits novel target in healthy volunteers at levels consistent with improved motor function in an animal model of Parkinson’s disease

Commercial Activities Advancing for Upcoming Launch of LibmeldyTM (atidarsagene autotemcel) for Eligible Patients with Early-onset MLD in Germany